GlassScriptPhysician profile
Daray Cortes
NPI 1871067439
$537.04
in general payments reported to CMS, 2019-2025
16 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2024: $190 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $115.59 | 2021-2024 | |
| Novo Nordisk INC | $56.85 | 2021 | |
| Hologic Sales and Service, LLC | $55.44 | 2024 | Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $53.09 | 2025 | The Cologuard Plus Collection Kit |
| Millicent US INC | $38.23 | 2021-2025 | Intrarosa, Femlyv |
| Pfizer INC. | $31.92 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.77 | 2025 | |
| Exeltis, USA INC. | $24.06 | 2024 | Slynd |
| Amarin Pharma, INC. | $23.78 | 2021 | |
| Sumitomo Pharma America, INC. | $21.24 | 2024 | Myfembree |
| Nestle Healthcare Nutrition INC. | $19.81 | 2021 | |
| Evofem Biosciences, INC. | $17.50 | 2024 | |
| Organon LLC | $15.13 | 2025 | Nexplanon |
| Coopersurgical, INC. | $14.33 | 2025 | Paragard T 380a |
| Currax Pharmaceuticals LLC | $13.63 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daray Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.